MDACC Study No:2012-0035 ( NCT No: NCT01633372)
Title:An Open-Label, Multiple Simon 2-Stage Study of INCB039110 Administered Orally to
Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera-Myelofibrosis (PPVMF)
or Post Essential Thrombocythemia-Myelofibrosis (PET-MF)
Principal Investigator:Srdan Verstovsek
Treatment Agent:INCB039110
Study Status:Closed
Study Description:The goal of this clinical research study is to study the effects of INCB039110
on spleen size and/or disease symptoms. Researchers want to learn about any
side effects that might occur during or after receiving the drug.
Hide details for General InformationGeneral Information

Disease Group:Myeloproliferative Diseases
Phase of Study:Phase II
Treatment Agents:INCB039110
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Incyte Corporation
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Srdan Verstovsek
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults